Arcadia Biosciences
RKDA
27 hedge funds and large institutions have $2.43M invested in Arcadia Biosciences in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 5 closing their positions.
120% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 5
29% more funds holding
Funds holding: 21 → 27 (+6)
0.09% less ownership
Funds ownership: 0.36% → 0.26% (-0.09%)
19% less call options, than puts
Call options by funds: $65K | Put options by funds: $80K
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
63% less capital invested
Capital invested by funds: $6.54M → $2.43M (-$4.11M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$552K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$413K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$105K |
| 4 |
MA
MYDA Advisors
Woodmere,
New York
|
+$65.3K |
| 5 |
D.E. Shaw & Co
New York
|
+$35.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
-$3.16M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$94.6K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$46.4K |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$27K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$18.5K |
RKDA Hedge Fund Activity: Q4 2021 in Review
27 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Arcadia Biosciences (RKDA) for Q4 2021, worth a combined $2.43M — down 63% from $6.54M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new RKDA positions and 5 closed out — a net gain of 6 holders — while 4 added to existing stakes and 6 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $552K. The largest seller was Ardsley Advisory Partners, exiting entirely with an estimated $3.16M sold.
- 27 institutional investors held Arcadia Biosciences (RKDA) as of Q4 2021, up from 21 in Q3 2021.
- Funds reported $2.43M of Arcadia Biosciences stock for Q4 2021, down 63% quarter-over-quarter.
- 11 funds opened new Arcadia Biosciences positions in Q4 2021 and 5 closed out, a net change of +6 holders.
- The largest Arcadia Biosciences buyer in Q4 2021 was Renaissance Technologies, an estimated $552K added.
- The largest Arcadia Biosciences seller in Q4 2021 was Ardsley Advisory Partners, an estimated $3.16M sold.
Based on aggregated 13F filings for Q4 2021.